CHICAGO (EGMN) – Final results from the Multicenter Italian Trials in Ovarian Cancer–2 show that carboplatin plus pegylated liposomal doxorubicin is no more effective than is the standard first-line chemotherapy of carboplatin plus paclitaxel for advanced ovarian cancer.
